Ebola Virus Entry: From Molecular Characterization to Drug Discovery

被引：54

作者：

Salata, Cristiano ^{[1
]}

Calistri, Arianna ^{[1
]}

Alvisi, Gualtiero ^{[1
]}

Celestino, Michele ^{[1
]}

Parolin, Cristina ^{[1
]}

Palu, Giorgio ^{[1
]}

机构：

[1] Univ Padua, Dept Mol Med, IT-35121 Padua, Italy

来源：

VIRUSES-BASEL | 2019年 / 11卷 / 03期

关键词：

Ebola virus; Filoviridae; VSV; retroviral vectors; virus-like particles; pseudovirus; antivirals; small molecules; viral entry; REVERSE GENETICS SYSTEMS; MATRIX PROTEIN VP40; ZAIRE-EBOLAVIRUS; CATHEPSIN-L; STRUCTURAL-CHARACTERIZATION; PSEUDOVIRUS INFECTION; VIRAL ENTRY; DC-SIGN; GLYCOPROTEIN; INHIBITORS;

D O I：

10.3390/v11030274

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Ebola Virus Disease (EVD) is one of the most lethal transmissible infections, characterized by a high fatality rate, and caused by a member of the Filoviridae family. The recent large outbreak of EVD in Western Africa (2013-2016) highlighted the worldwide threat represented by the disease and its impact on global public health and the economy. The development of highly needed anti-Ebola virus antivirals has been so far hampered by the shortage of tools to study their life cycle in vitro, allowing to screen for potential active compounds outside a biosafety level-4 (BSL-4) containment. Importantly, the development of surrogate models to study Ebola virus entry in a BSL-2 setting, such as viral pseudotypes and Ebola virus-like particles, tremendously boosted both our knowledge of the viral life cycle and the identification of promising antiviral compounds interfering with viral entry. In this context, the combination of such surrogate systems with large-scale small molecule compounds and haploid genetic screenings, as well as rational drug design and drug repurposing approaches will prove priceless in our quest for the development of a treatment for EVD.

引用

页数：20

共 115 条

[51] FDA-Approved Selective Estrogen Receptor Modulators Inhibit Ebola Virus Infection [J].

Johansen, Lisa M. ;

Brannan, Jennifer M. ;

Delos, Sue E. ;

Shoemaker, Charles J. ;

Stossel, Andrea ;

Lear, Calli ;

Hoffstrom, Benjamin G. ;

DeWald, Lisa Evans ;

Schornberg, Kathryn L. ;

Scully, Corinne ;

Lehar, Joseph ;

Hensley, Lisa E. ;

White, Judith M. ;

Olinger, Gene G. .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (190)

[52] Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells [J].

Johnson, Joshua C. ;

Martinez, Osvaldo ;

Honko, Anna N. ;

Hensley, Lisa E. ;

Olinger, Gene G. ;

Basler, Christopher F. .

ANTIVIRAL RESEARCH, 2014, 107 :102-109

[53] T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus [J].

Kondratowicz, Andrew S. ;

Lennemann, Nicholas J. ;

Sinn, Patrick L. ;

Davey, Robert A. ;

Hunt, Catherine L. ;

Moller-Tank, Sven ;

Meyerholz, David K. ;

Rennert, Paul ;

Mullins, Robert F. ;

Brindley, Melinda ;

Sandersfeld, Lindsay M. ;

Quinn, Kathrina ;

Weller, Melodie ;

McCray, Paul B., Jr. ;

Chiorini, John ;

Maury, Wendy .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (20) :8426-8431

[54] Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs [J].

Kouznetsova, Jennifer ;

Sun, Wei ;

Martinez-Romero, Carles ;

Tawa, Gregory ;

Shinn, Paul ;

Chen, Catherine Z. ;

Schimmer, Aaron ;

Sanderson, Philip ;

McKew, John C. ;

Zheng, Wei ;

Garcia-Sastre, Adolfo .

EMERGING MICROBES & INFECTIONS, 2014, 3

[55] Blood kinetics of Ebola virus in survivors and nonsurvivors [J].

Lanini, Simone ;

Portella, Gina ;

Vairo, Francesco ;

Kobinger, Gary P. ;

Pesenti, Antonio ;

Langer, Martin ;

Kabia, Soccoh ;

Brogiato, Giorgio ;

Amone, Jackson ;

Castilletti, Concetta ;

Miccio, Rossella ;

Zumla, Alimuddin ;

Capobianchi, Maria Rosaria ;

Di Caro, Antonino ;

Strada, Gino ;

Ippolito, Giuseppe .

JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (12) :4692-4698

[56] Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor [J].

Lee, Jeffrey E. ;

Fusco, Marnie L. ;

Hessell, Ann J. ;

Oswald, Wendelien B. ;

Burton, Dennis R. ;

Saphire, Erica Ollmann .

NATURE, 2008, 454 (7201) :177-U27

[57] Ebolavirus glycoprotein structure and mechanism of entry [J].

Lee, Jeffrey E. ;

Saphire, Erica Ollmann .

FUTURE VIROLOGY, 2009, 4 (06) :621-635

[58] High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-like particle system [J].

Lee, Nakyung ;

Shum, David ;

Konig, Alexander ;

Kim, Hichul ;

Heo, Jinyeong ;

Min, Saehong ;

Lee, Jihye ;

Ko, Yoonae ;

Choi, Inhee ;

Lee, Honggun ;

Radu, Constantin ;

Hoenen, Thomas ;

Min, Ji-Young ;

Windisch, Marc P. .

ANTIVIRAL RESEARCH, 2018, 158 :226-237

[59] Novel cyclo-peptides inhibit Ebola pseudotyped virus entry by targeting primed GP protein [J].

Li, Quanjie ;

Ma, Ling ;

Yi, Dongrong ;

Wang, Han ;

Wang, Jing ;

Zhang, Yongxin ;

Guo, Ying ;

Li, Xiaoyu ;

Zhou, Jinining ;

Shi, Yi ;

Gao, George F. ;

Cen, Shan .

ANTIVIRAL RESEARCH, 2018, 155 :1-11

[60] Phenotypic Prioritization of Diphyllin Derivatives That Block Filoviral Cell Entry by Vacuolar (H+)-ATPase Inhibition [J].

Lindstrom, Aaron ;

Anantpadma, Manu ;

Baker, Logan ;

Raghavendra, N. M. ;

Davey, Robert ;

Davisson, Vincent Jo .

CHEMMEDCHEM, 2018, 13 (24) :2664-2676

← 1 2 3 4 5 6 7 8 9 10 →